GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025

GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study

GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update

GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy

GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®

GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024

GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings